Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 0.40 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26881403 | 0.92 | SETD2 (0.47) | NOTUMSETD2MCHR1NPY5RPIK3CD | |
| SCHEMBL25966618 | 0.92 | SETD2 (0.47) | NOTUMSETD2MCHR1NPY5RPIK3CD | |
| SCHEMBL3723644 | 0.87 | HTR6 (0.38) | NOTUMMCHR1 | |
| SCHEMBL14322213 | 0.85 | NPY5R (0.42) | SETD2MCHR1NPY5RPIK3CD | |
| SCHEMBL30814862 | 0.85 | NPY5R (0.42) | SETD2MCHR1NPY5RPIK3CD | |
| SCHEMBL26881409 | 0.83 | NPY5R (0.39) | NPY5RPIK3CD | |
| SCHEMBL25966195 | 0.83 | NPY5R (0.39) | NPY5RPIK3CD | |
| SCHEMBL13420961 | 0.82 | NOTUM (0.60) | NOTUM | |
| SCHEMBL902233 | 0.82 | NOTUM (0.35) | NOTUMNPY5R | |
| SCHEMBL2190473 | 0.82 | LPL (0.39) | SETD2NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573943-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20140128376-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8669361-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-11 | — | — | US | disclosed |
| US-20130203732-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-8436001-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128376-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | NOTUM 3957/4885SETD2 4667/4885MCHR1 3999/4885 |
| US-20130203732-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | NOTUM 3957/4885SETD2 4667/4885MCHR1 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.